Which medications in the drug class NMDA Antagonists are used in the treatment of Parkinson Disease?

Updated: Aug 29, 2019
  • Author: Robert A Hauser, MD, MBA; Chief Editor: Selim R Benbadis, MD  more...
  • Print

NMDA Antagonists

Persistent activation of CNS N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of dementia. Agents such as memantine, which is an NMDA receptor antagonist, can prevent activation of the NMDA receptors.

Memantine (Namenda, Namenda XR)

Memantine is approved for the treatment of moderate to severe dementia in Alzheimer disease. Initial dosage is 5 mg once daily for immediate-release tablets and 7 mg once daily for extended-release tablets. Dosage titration may be required based on clinical response.

Memantine is postulated to exert its therapeutic effect through its action as a low- to moderate-affinity, uncompetitive NMDA receptor antagonist. Blockade of NMDA receptors by memantine slows the intracellular calcium accumulation and helps prevent further nerve damage.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!